Fludarabine

T-Cell Non-Hodgkin Lymphoma

Beijing GoBroad HospitalSmall moleculePhase 3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 89/ 100

Competitive context

6 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Anti-Thymoglobulin, Rabbit Stanford University	Phase 2	BB
CYCLOSPORIN A Robert Lowsky	Phase 2	B
FILGRASTIM Dana-Farber Cancer Institute	Phase 2	B
CENTRAL MEMORY T-CELLS (AUTOLOGOUS) Robert Lowsky	Phase 2	B
Allogeneic Cluster Of Differentiation 8 + Memory T-Cells Robert Lowsky	Phase 2	B

View all 14 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Fanconi anemiaDormant

BBB

Indicative ·

76 / 100

Recurrent Adult Diffuse Large Cell LymphomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.